Bio-Rad Laboratories (NYSE:BIO) – Research analysts at Jefferies Group raised their Q2 2018 EPS estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Monday, April 16th. Jefferies Group analyst B. Couillard now expects that the medical research company will earn $1.17 per share for the quarter, up from their previous estimate of $0.93. Jefferies Group has a “Buy” rating and a $325.00 price target on the stock. Jefferies Group also issued estimates for Bio-Rad Laboratories’ Q3 2018 earnings at $1.33 EPS.
Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.22. The business had revenue of $620.43 million for the quarter, compared to analyst estimates of $618.89 million. Bio-Rad Laboratories had a return on equity of 3.63% and a net margin of 5.31%.
Shares of BIO stock opened at $262.26 on Wednesday. The firm has a market cap of $7,877.67, a P/E ratio of 63.97, a PEG ratio of 3.08 and a beta of 0.94. Bio-Rad Laboratories has a twelve month low of $208.95 and a twelve month high of $279.59. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.93.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC grew its position in shares of Bio-Rad Laboratories by 297.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 560 shares of the medical research company’s stock valued at $134,000 after buying an additional 419 shares during the last quarter. Private Advisor Group LLC bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at about $248,000. Macquarie Group Ltd. bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $255,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Bio-Rad Laboratories by 42.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock valued at $278,000 after buying an additional 350 shares during the last quarter. Finally, Advisory Services Network LLC grew its position in shares of Bio-Rad Laboratories by 218.6% in the 4th quarter. Advisory Services Network LLC now owns 1,217 shares of the medical research company’s stock valued at $290,000 after buying an additional 835 shares during the last quarter. Hedge funds and other institutional investors own 64.52% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2018/04/20/q2-2018-earnings-forecast-for-bio-rad-laboratories-issued-by-jefferies-group-bio.html.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.